Guggenheim Sees Compass (CMPX) Potential Driven by Biliary Tract Cancer Pipeline

Group 1 - Compass Therapeutics Inc. (NASDAQ:CMPX) is identified as a promising multibagger stock, with its lead program CTX-009 targeting advanced solid tumors, particularly biliary tract cancer (BTC), which presents a market opportunity exceeding $1 billion [1] - Approximately 85% of BTC patients who fail first-line therapy currently lack approved and effective treatment options, highlighting a significant unmet medical need [1] - Analyst Michael Schmidt from Guggenheim raised the price target for Compass Therapeutics to $12 from $10, maintaining a Buy rating following positive Q2 results and pipeline updates [2] Group 2 - The management updated the timeline for the COMPANION-002 Phase 2/3 trial of tovecimig in biliary tract cancer, with final progression-free survival and overall survival data now expected in early 2026, slightly delayed from the previous estimate of Q4 2025 [3] - Despite the delay, the trial is still considered a key near-term catalyst for the company [3] - Schmidt's report reflects increased confidence in the company's pipeline, particularly in tovecimig and CTX-8371, which are seen as having clinical and commercial potential [4][5]